CITIUS ONCOLOGY, INC. (CTOR) Stock Price, Financials & Summary

Price chart

Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29

Key dataOct 29, 2026

Open$0.58

From 52W high−69.43%

Volume146994.00

Market cap$49.74M

P/E (TTM)—

P/S (TTM)7.0x

Div yield—

Key dataOct 29, 2026

Open

$0.58

From 52W high

−69.43%

Volume

146994.00

Market cap

$49.74M

ValuationView details →

P/E (Fwd)

2.7x

EV/EBITDA

−1.0x

P/E (TTM)

—

RSI (14)

24.9

MomentumView details →

1D Return

−7.25%

YTD Return

−48.94%

SummaryUpdated Jun 1, 2026

Citius Oncology, Inc. (NASDAQ:CTOR) is a clinical-stage biopharmaceutical company founded as a subsidiary of Citius Pharmaceuticals, Inc. and headquartered in New York, New York. The company specializes in developing novel targeted therapies for cancer treatment, with a particular focus on rare blood cancers. Citius Oncology operates as a pre-revenue biotech company, currently advancing its lead drug candidate LYMPHIR through clinical trials for the treatment of cutaneous T-cell lymphoma, a rare form of blood cancer that affects the skin.

Ask drillr about CITIUS ONCOLOGY, INC. →

ValuationView details →

P/E (Fwd)

2.7x

P/E (TTM)

—

EV/EBITDA

−1.0x

EV/Sales

6.1x

P/S (TTM)

7.0x

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

53.13%

Net Margin

−648.32%

EBITDA Margin

−607.02%

ROE (TTM)

−114.06%

ROA (TTM)

−41.09%

Asset Turnover

0.07x

GrowthView details →

Revenue YoY

—

EPS YoY

−27.12%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−13.33%

EBITDA YoY

−69.27%

MomentumView details →

1D Return

−7.25%

YTD Return

−48.94%

1Y Return

−70.49%

RSI (14)

24.9

vs 50D SMA

−39.25%

vs 200D SMA

−39.04%

Capital & dividendView details →

Debt/Equity

0.25x

Current Ratio

0.73x

Quick Ratio

0.34x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.08

EPS Surprise

−14.29%

Beats (12Q)

2/12

Next Q EPS Est

$0.10

Avg Surprise (4Q)

−666.07%

Rev Surprise

−40.25%

Financials snapshotView financials →

Revenue (TTM)

7.11M

Net Income (TTM)

−46.06M

Op. CF (TTM)

−19.71M

Next earningsDec 17, 2026 →

Latest newsMore news →

Citius Oncology, Inc. reported its Q3 2026 financial results, with revenue of $1.5 million and a net loss of $8.9 million.77d ago

Similar companies

MIRA Pharmaceuticals, Inc.MIRA Scilex Holding CompanySCLX Modern Chinese Medicine Group Co., Ltd.01643.HK Bristol-Myers Squibb Company CeCELG-RI Beijing Biostar Pharms Co Ltd02563.HK TYK Medicines, Inc02410.HK Find similar companies →

Latest newsMore news →

Citius Oncology reported 792 wholesaler units and 950 institutional vial orders in Q4 2026, with 54 institutions ordering; wholesaler units rose 120% from the prior quarter, while institutional vial orders increased from 926.3d ago Citius Oncology, Inc. reported its Q3 2026 financial results, with revenue of $1.5 million and a net loss of $8.9 million.77d ago